AbbVie Inc. Non-operating Interest Expenses

Non-operating Interest Expenses of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including Non-operating Interest Expenses growth rates and interactive chart. Interest expense that is usually non-recurring and not tied to a company's operations. It is stated separately on the income statement to differentiate it from interest expenses.


Highlights and Quick Summary

  • Non-operating Interest Expenses for the quarter ending September 29, 2020 was $620 Million (a 0.98% increase compared to previous quarter)
  • Year-over-year quarterly Non-operating Interest Expenses increased by 36.26%
  • Annual Non-operating Interest Expenses for 2019 was $1.51 Billion (a 31.91% increase from previous year)
  • Annual Non-operating Interest Expenses for 2018 was $1.14 Billion (a 13.94% increase from previous year)
  • Annual Non-operating Interest Expenses for 2017 was $1 Billion (a 4.04% increase from previous year)
  • Twelve month Non-operating Interest Expenses ending September 29, 2020 was $2.12 Billion (a 10.43% increase compared to previous quarter)
  • Twelve month trailing Non-operating Interest Expenses increased by 40.29% year-over-year
Trailing Non-operating Interest Expenses for the last four month:
29 Sep '20 29 Jun '20 30 Mar '20 30 Dec '19
$2.12 Billion $1.92 Billion $1.61 Billion $1.51 Billion
Visit stockrow.com/ABBV for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Non-operating Interest Expenses of AbbVie Inc.

Most recent Non-operating Interest Expensesof ABBV including historical data for past 10 years.

Interactive Chart of Non-operating Interest Expenses of AbbVie Inc.

AbbVie Inc. Non-operating Interest Expenses for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $620.0 $614.0 $428.0
2019 $455.0 $420.0 $309.0 $325.0 $1,509.0
2018 $319.0 $302.0 $272.0 $251.0 $1,144.0
2017 $252.0 $252.0 $253.0 $247.0 $1,004.0
2016 $290.0 $250.0 $225.0 $200.0 $965.0
2015 $199.0 $197.0 $164.0 $126.0 $686.0
2014 $129.0 $128.0 $69.0 $65.0 $391.0
2013 $68.0 $69.0 $75.0 $66.0 $278.0
2012 $88.0 $-1.0 $-2.0 $-1.0 $84.0
2011 $-20.0 $0.0 $0.0 $-20.0
2010 $-28.0

Business Profile of AbbVie Inc.

Sector: Healthcare
Industry: Drug Manufacturers—General
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides SYNAGIS that protects at-risk infants from severe respiratory disease; KALETRA, a prescription anti-HIV-1 medicine; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; and Lupron, a product for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; and Sevoflurane, an anesthesia product. It has collaborations with Calico Life Sciences LLC; Alector, Inc.; Janssen Biotech, Inc.; Jacobio Pharmaceuticals; I-Mab; and Genmab A/S. The company was incorporated in 2012 and is based in North Chicago, Illinois.